Topics

Clinical Trials About "Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet" RSS

16:56 EST 8th December 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet" on BioPortfolio

We have published hundreds of Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet news stories on BioPortfolio along with dozens of Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet Clinical Trials and PubMed Articles about Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet Companies in our database. You can also find out about relevant Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet Drugs and Medications on this site too.

Showing "Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet" Clinical Trials 1–25 of 30,000+

Relevant

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

The purpose of this study is to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.


Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.

Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)

The purpose of this study is to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.


Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets

The sponsor, Pfizer has developed a formulation of tramadol hydrochloride/ paracetamol 37.5 mg/ 325 mg (test drug) as a generic alternative to the reference listed product Ultracet®. In order to meet the requirements for registration as a generic drug, this study is being conducted to demonstrate the bioequivalence between the formulation of tramadol hydrochloride/ paracetamol 37.5 mg/ 325 mg provided by Pfizer and the reference drug tramadol hydrochloride/ paracetamol 37.5 mg...

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer

In case of gastric cancer, the incidence of HER-2 positivity (2+, 3+ on IHC and/or FISH (+)) is reported as similar as that of breast cancer, that is 22% of all cases. A recent ToGA Trial, phase III trial comparing trastuzumab combined with chemotherapy (fluoropyrimidine+cisplatin) versus chemotherapy alone in chemotherapy-naïve HER-2 (+) gastric cancer shows the significant benefit of using trastuzumab in terms of overall survival and progression-free survival. It provides th...

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Serono) when administered in patients undergoing ICSI

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine)* clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, START and INSPIRE. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. More information c...

Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients

Gastric cancer have poor prognosis and majority of patients resistant to 5-FU/DDP based first-line chemotherapy in China. There was no recommended second-line chemotherapy for advanced gastric cancer. Taxane is promising in gastric cancer. Nanoparticle Albumin-Bound Paclitaxel (Abraxane,ABI-007) has good convenience to use and been approved in breast cancer in many countries. The investigator then initiated a prospective phase Ib/IIa clinical trial with nab-paclitaxel plus TS...

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers

A Trial of RAD001/Capecitabine in Refractory Gastric Cancer

Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory gastric cancer patients.

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.

A Prospective, Single Arm, Open Phase II Clinical Trial of Adjuvant Treatment of Stage III Gastric Cancer (PD-L1 + / MSI-H / EB +) With Anti-PD-1 Antibody and First-line Chemotherapy

To evaluate the efficacy and safety of Erika combined with first-line chemotherapy in the treatment of stage III gastric cancer (PD-L1 + / MSI-H / EB +). Secondary study objective: To observe and evaluate the overall survival and adverse events of Erika combined with first-line chemotherapy in patients with stage III gastric cancer (PD-L1 + / MSI-H / EB +). To evaluate the safety of Erika combined with first-line chemotherapy in the treatment of stage III gastric cancer (PD-L1 ...

Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices

To see if removing the omentum in addition to a gastric bypass improves diabetes is better than just a gastric bypass.

Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma

The objective of the trial is to compare disease-free survival between adjuvant capecitabine/cisplatin alone vs capecitabine/cisplatin with radiotherapy (chemoradiation) in curatively resected gastric cancer patients.

Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer

The purpose of this study is to explore the efficacy of adjuvant radiotherapy for D2 resected gastric cancer

A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research

Background: - Individuals often participate in clinical trials to seek new therapies and free medical treatments for their illnesses or chronic conditions. However, less is known about the motivations of the healthy individuals who volunteer for research studies. - Although many healthy volunteers participate in clinical trials for financial compensation, the particular risks involved in testing drugs that have not been tried in human clinical ...

Clinical Trial for Laparoscopic D2 Gastrectomy

Phase II study to determine whether laparoscopy-assisted distal gastrectomy (LADG) with complete D2 lymph node dissection for gastric cancer is a safe and effective surgical option.

Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative gastric cancer

Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase I/II study of this combination in patients with inoperable or with postoperative gastric cancer

Proteiomic Fingerprints of Gastric Juice

No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potential biomarkers of gastric cancer in gastric juice. The aim of this study was to develop a novel non-invasive modality for detecting gastric cancer by measurement of biomarkers in gastric juice.

Laparoscopic Gastric Bypass Versus Laparoscopic Banded Gastric Bypass Randomized Prospective Clinical Trial

This study try to identify differences in length of operation, weight loss and complications, between two different bariatric surgical techniques, the laparoscopic Roux-en-Y gastric bypass and the laparoscopic Roux-en-Y banded gastric bypass. The study will be conducted in a Spanish public health system hospital. The patients of the trial will have the preoperative studies, hospital treatment during the admission, postoperative treatment and follow up as any other patient inclu...

Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer

This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy. Phase 1 was designed to determine the optimal dose of pemetrexed for its phase 2, which has been completed and now a total of 60 qualified patients will be enrolled in the phase 2 of this study. The treating physician will determined the maximum number of cycles of pemetrexed plus cisplatin...

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

In previous studies,the investigators found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer. Apatinib is an orally antiangiogenic agent. It was approved and launched in China in 2014 as a 3rd-line treatment for patients with advanced gastric cancer. Therefore, investigators conducted the dose escalation phase I study to explore the safety of combination of ...

Study of the Combination of Apatinib and POF

In previous studies, we found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer. Apatinib is an orally antiangiogenic agent. It was approved and launched in China in 2014 as a 3rd-line treatment for patients with advanced gastric cancer. Therefore, investigators conducted the dose escalation phase I study to explore the safety of combination of apatinib and P...

A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects

The primary objective of the study is to determine bioequivalence of 50 mg (2x25 mg) Artesunate Sachet (Pfizer) versus 50 mg (1x50 mg) tablet, Arsuamoon® (Guilin China) which is the World Health Organization Reference standard for artesunate The secondary objective is to assess the safety of Artesunate Sachet (Pfizer) and Arsuamoon® tablet (Guilin China).


More From BioPortfolio on "Serono Pfizer Phase JAVELIN GASTRIC Trial Fails Meet"

Quick Search